Protocol to generate traceable CAR T cells for syngeneic mouse cancer models

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell immunotherapy efficacy is hindered by the immunosuppressive tumor microenvironment, limiting T-cell infiltration and activation.
• Understanding resistance mechanisms is crucial for advancing CAR T-cell therapy in cancer treatment.

Purpose of the Study:

• To present a detailed protocol for preparing mouse T-cells and generating CAR T-cells.
• To outline procedures for evaluating the therapeutic efficacy and tracking CAR T-cells in a syngeneic mouse glioma model.

Main Methods:

• Protocol development for mouse T-cell preparation and CAR T-cell generation.
• In vivo testing of CAR T-cell therapeutic efficacy in immunocompetent mouse cancer models.
• Tracking of CAR T-cells within a syngeneic mouse glioma model.

Main Results:

• The study provides a comprehensive protocol for CAR T-cell generation and evaluation in preclinical models.
• The protocol facilitates the study of immunotherapy resistance mechanisms in the tumor microenvironment.
• Successful application of the protocol in a syngeneic mouse glioma model.

Conclusions:

• The presented protocol enables robust preclinical evaluation of CAR T-cell immunotherapy in mouse cancer models.
• This methodology aids in defining mechanisms of resistance and optimizing CAR T-cell therapy.
• The protocol serves as a valuable resource for researchers investigating CAR T-cell efficacy against solid tumors.